// App-Quantinova.ai

8000 : Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.

Researchers

Presenter

  • Andrzej J. Jakubowiak

Principal Investigators

  • Ajai Chari

  • Sagar Lonial

  • Brendan M. Weiss

  • Raymond L. Comenzo

  • Kaida Wu

  • Nushmia Z. Khokhar

  • Jianping Wang

  • Parul Doshi

  • Saad Zafar Usmani

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

  • Abramson Cancer Center, Philadelphia, PA

  • Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

Locations

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Sparsentan

Outcome

  • Positive

Study Design

  • Open Label

Phase

  • I

Study Id's

  • NCT01998971

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved